Dr. Behfar Ehdaie

Well, that's a low stakes trial. Obviously, no one's going to have a massive adverse event from that. So we thought that was a good trial to randomize patients and use this concept of two-stage consent, which was saying we would consent patients to say, we are interested in reducing pain and discomfort and improve the biopsy experience.

Well, that's a low stakes trial. Obviously, no one's going to have a massive adverse event from that. So we thought that was a good trial to randomize patients and use this concept of two-stage consent, which was saying we would consent patients to say, we are interested in reducing pain and discomfort and improve the biopsy experience.

Well, that's a low stakes trial. Obviously, no one's going to have a massive adverse event from that. So we thought that was a good trial to randomize patients and use this concept of two-stage consent, which was saying we would consent patients to say, we are interested in reducing pain and discomfort and improve the biopsy experience.

And would you sign up for us to approach you in the future at random if there is something that may benefit? And today you're signing up for us to continue to monitor your outcomes and record those as part of a clinical trial. Of course, no patient says no to that. There's no intervention. There's no secondary study. And all I'm asking for is record your outcomes.

And would you sign up for us to approach you in the future at random if there is something that may benefit? And today you're signing up for us to continue to monitor your outcomes and record those as part of a clinical trial. Of course, no patient says no to that. There's no intervention. There's no secondary study. And all I'm asking for is record your outcomes.

And would you sign up for us to approach you in the future at random if there is something that may benefit? And today you're signing up for us to continue to monitor your outcomes and record those as part of a clinical trial. Of course, no patient says no to that. There's no intervention. There's no secondary study. And all I'm asking for is record your outcomes.

And then after they sign that consent, they go home. They get placed in our pool of patients in our trial for biopsy experience. And we randomly select one group that we approach at their biopsy and say, hey, remember when we spoke about our initial discussion that we're looking for ways to improve and we may randomly select you for something if we think it might benefit you?

And then after they sign that consent, they go home. They get placed in our pool of patients in our trial for biopsy experience. And we randomly select one group that we approach at their biopsy and say, hey, remember when we spoke about our initial discussion that we're looking for ways to improve and we may randomly select you for something if we think it might benefit you?

And then after they sign that consent, they go home. They get placed in our pool of patients in our trial for biopsy experience. And we randomly select one group that we approach at their biopsy and say, hey, remember when we spoke about our initial discussion that we're looking for ways to improve and we may randomly select you for something if we think it might benefit you?

Well, you were selected and this is the intervention. We're going to give you a headphone. You're going to listen. Are you interested in enrolling in the study? There's no 50% chance that patient's going to get the other side of the token. At that point, they just need to hear about what they've been randomized to because the other option is just standard of care, go do your biopsy and leave.

Well, you were selected and this is the intervention. We're going to give you a headphone. You're going to listen. Are you interested in enrolling in the study? There's no 50% chance that patient's going to get the other side of the token. At that point, they just need to hear about what they've been randomized to because the other option is just standard of care, go do your biopsy and leave.

Well, you were selected and this is the intervention. We're going to give you a headphone. You're going to listen. Are you interested in enrolling in the study? There's no 50% chance that patient's going to get the other side of the token. At that point, they just need to hear about what they've been randomized to because the other option is just standard of care, go do your biopsy and leave.

So that conversation, when it's easier, I was allowed to be excited about this new intervention and speak to them and answer their questions. They were well-informed and then we would collect their data. And it essentially is a randomized controlled trial because those patients were randomly selected after enrollment.

So that conversation, when it's easier, I was allowed to be excited about this new intervention and speak to them and answer their questions. They were well-informed and then we would collect their data. And it essentially is a randomized controlled trial because those patients were randomly selected after enrollment.

So that conversation, when it's easier, I was allowed to be excited about this new intervention and speak to them and answer their questions. They were well-informed and then we would collect their data. And it essentially is a randomized controlled trial because those patients were randomly selected after enrollment.

And I remember we looked at this data, which we published recently, and looked at specifically patient anxiety, patient understanding clinical trial, feelings of autonomy, and those were off the charts compared to traditional randomized controlled trials that we use in historic data.

And I remember we looked at this data, which we published recently, and looked at specifically patient anxiety, patient understanding clinical trial, feelings of autonomy, and those were off the charts compared to traditional randomized controlled trials that we use in historic data.

And I remember we looked at this data, which we published recently, and looked at specifically patient anxiety, patient understanding clinical trial, feelings of autonomy, and those were off the charts compared to traditional randomized controlled trials that we use in historic data.

So it was very clear to us that reducing the burden at the time of consent actually created more informed consent, less anxiety, and increase our enrollment into clinical trials. And so that was the next pearl, which was to really take the concept of the standard randomized controlled trial discussion and modify it to this integrated trial if you're comparing it to a standard of care procedure.

So it was very clear to us that reducing the burden at the time of consent actually created more informed consent, less anxiety, and increase our enrollment into clinical trials. And so that was the next pearl, which was to really take the concept of the standard randomized controlled trial discussion and modify it to this integrated trial if you're comparing it to a standard of care procedure.